Given the tumor microenvironment and the patient’s baseline condition, chemotherapy was abandoned in favor of combination therapy consisting of a TKI, which can reduce inflammation and fibrogenesis, and PD-1 blockade. This evidence concerns the gene PDCD1 and neoplasm.